Department of Medicinal Chemistry, NanChang University School of Pharmaceutical Science, NanChang, PR China.
J Enzyme Inhib Med Chem. 2011 Apr;26(2):222-30. doi: 10.3109/14756366.2010.491794. Epub 2010 Jun 22.
The CB1 receptor belongs to the G-protein-coupled receptor superfamily. CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. In this study, we report the synthesis and in vitro binding affinity assay of some 1,5-diarylpyrazole scaffold compounds. The binding results showed that some of the target compounds had an excellent potency toward the CB1 receptor with IC₅₀ values lying at the nanomole level.
CB1 受体属于 G 蛋白偶联受体超家族。CB1 拮抗作用被认为是治疗肥胖症的新的治疗靶点。在本研究中,我们报告了一些 1,5-二芳基吡唑骨架化合物的合成和体外结合亲和力测定。结合结果表明,一些目标化合物对 CB1 受体具有优异的活性,半数抑制浓度(IC₅₀)值处于纳摩尔水平。